Medical devices, healthcare technology and the business of care
510(k) clearance · K260360

AesyBite Active

Aesyra SA · Decision date Oct 30, 2026

FDA DECISIONK260360

What did the FDA decide?

FDA records K260360 as a 510(k) premarket notification, with a decision dated Oct 30, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Oct 30, 2026

FDA source record

Regulatory record facts

Identifier
K260360
Regulatory pathway
510(k) premarket notification
Applicant
Aesyra SA
Product code
HCC
Decision code
SESE
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, Biofeedback.

Applicant
Aesyra SA
Product code
HCC
FDA device class
2

FDA decision timeline

  1. K260360 received

    Application receipt date recorded by FDA.

  2. K260360 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Aesyra SA

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Lausanne

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records